Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 52

Sort by

Sort Order Select

Journal Articles

CD19 expression is preserved following CD19-directed monoclonal antibody therapy with tafasitamab

Johannes Duell, Diana Alvarez Arias, Wolfram Klapper, Sarah Reinke, Florian Eisele, Thomas Larsen, Prof. Dr. Max S Topp, Beth Rumberger, TaeHyung (Simon) Kim, Andreas Rosenwald, Hilka Rauert-Wunderlich

Blood (2025) 146 (Supplement 1): 5515.

https://doi.org/10.1182/blood-2025-5515

Published: 2025

Journal Articles

Fixed-duration epcoritamab monotherapy induces high response and MRD-negativity rates in elderly patients with newly diagnosed large B-cell lymphoma (LBCL) and comorbidities: Results from EPCORE DLBCL-3

Blood (2025) 146 (Supplement 1): 63.

https://doi.org/10.1182/blood-2025-63

Published: 2025

Journal Articles

Phase II frontline chemolight R-pola-glo trial induces high and durable response rates in elderly and medically unfit/frail patients with aggressive B-cell lymphoma

Blood (2025) 146 (Supplement 1): 61.

https://doi.org/10.1182/blood-2025-61

Published: 2025

Journal Articles

Endothelial dysfunction and proinflammatory state determine severe hematotoxicity and adverse outcome of CAR-T therapy

Blood (2025) 146 (Supplement 1): 809.

https://doi.org/10.1182/blood-2025-809

Published: 2025

Journal Articles

Increased teclistamab dosing interval improves T-cell diversity and reduces infection risk, while T-cell exhaustion remains minimal irrespective of schedule

Blood (2025) 146 (Supplement 1): 802.

https://doi.org/10.1182/blood-2025-802

Published: 2025

Journal Articles

Efficacy and safety of vipor (P) in relapsed or refractory large B-cell lymphoma

Thomas Oellerich, Rebecca Wurm-Kuczera, Shashwat Sahay, Meng Wang, Salaheddine Ali, Nazli Serin, Khouloud Kouidri, Donika Tahiri, Sebastian Scheich, Uta Brunnberg, David Winkler, Samixa Pudasaini, Zoi Saxonis, Atef Abdelhafez, Tatiana Borodina, Ulrike Krueger, David Böckle, Corinna Leng, Joseph Kauer, Isabelle Krämer, Konstantinos Christofyllakis, Marcel Teichert, Niklas Gebauer, Ulf Schnetzke, Thomas Weber, Lukas Frenzel, Anna-Carina Hund, Evgenii Shumilov, Thomas Melchardt, Florian Eisele, Mirjeta Berisha, Jakob Rudzki, Christian Scholz, Martin Schmidt-Hieber, Dimitrios Mougiakakos, Johannes Duell, Gerald Wulf, Christian Schmidt, Georg Lenz, Bastian von Tresckow, Hans Christian Reinhardt, Richard Greil, Lorenz Thurner, Peter Dreger, Martin Dreyling, Christiane Pott, Martina Rudelius, Oliver Weigert, Phillipp Strubel, Roland Eils, Antonia Busse, Ulrich Keller, Naveed Ishaque, Björn Chapuy

Blood (2025) 146 (Supplement 1): 3688.

https://doi.org/10.1182/blood-2025-3688

Published: 2025

Journal Articles

Spatial transcriptomics reveals profound subclonal heterogeneity and T-cell dysfunction in extramedullary myeloma

Blood (2024) 144 (20): 2121–2135.

https://doi.org/10.1182/blood.2024024590

Published: 2024

Includes: Supplemental data

Journal Articles

Tracking Bone Marrow Regeneration after CAR-T Cell Therapy in Myeloma at Spatial Single-Cell Resolution Reveals Determinants of Prolonged Cytopenia

Jennifer Wing Lam Cheung, Prachurjya Panda, Xiang Zhou, Katrin Sinning, Ankit Agrawal, Andy Shing Fung Chan, Johannes Duell, Johannes Waldschmidt, Hermann Einsele, Martin Väth, Andreas Rosenwald, Dominic Grün, Leo Rasche

Blood (2024) 144 (Supplement 1): 4639.

https://doi.org/10.1182/blood-2024-203052

Published: 2024

Journal Articles

Classic Anti-Myeloma Treatments Alter Circulating Immune Cell Subsets with Potential Implications for T Cell Immunotherapies in Multiple Myeloma

Xiang Zhou, Sarah Wiethe, Angelika Wolff, Max J Steinhardt, Nazia Afrin, Mara John, Christine Riedhammer, Xianghui Xiao, Umair Munawar, Julia Mersi, Seungbin Han, Johannes Waldschmidt, Angela Riedel, Max S. Topp, Johannes Duell, Hermann Einsele, K. Martin Kortüm, Leo Rasche

Blood (2024) 144 (Supplement 1): 4705.

https://doi.org/10.1182/blood-2024-203391

Published: 2024

Journal Articles

Epcore DLBCL-3 First Disclosure: Fixed-Duration Epcoritamab Monotherapy in Older (≥75 y), Anthracycline-Ineligible Patients with Previously Untreated Large B-Cell Lymphoma

Franck Morschhauser, David Belada, Johannes Duell, Wojciech Jurczak, Tae Min Kim, Won Seog Kim, Takahiro Kumode, Javier López Jiménez, Caressa Meert, Sergio Ortegon Alcaide, Catherine Thieblemont, Yajian Jiang, Mina Khoshdeli, Yanli Wang, Evelyn Guo, Daniela Hoehn, Sherida Woei-A-Jin

Blood (2024) 144 (Supplement 1): 867.

https://doi.org/10.1182/blood-2024-199271

Published: 2024

Journal Articles

IDH2 Mutations from Clonal Hematopoiesis and Acquired IKZF1 Deletions Define a Novel B-ALL Subtype after Lenalidomide Therapy for Multiple Myeloma

Blood (2024) 144 (Supplement 1): 631.

https://doi.org/10.1182/blood-2024-199601

Published: 2024

Journal Articles

The Role of Clonally Expanded CD8 + Non-CAR-T Cells in Neurocognitive and Hypokinetic Movement Disorder after BCMA-Targeting CAR-T Cell Therapy

Blood (2024) 144 (Supplement 1): 7086.

https://doi.org/10.1182/blood-2024-202348

Published: 2024

Journal Articles

Maintenance of CD19 Expression after Tafasitamab Treatment in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) from Clinical Trial and Real-World Settings

Johannes Duell, Diana Alvarez Arias, Hilka Rauert-Wunderlich, Florian Eisele, Alla Volgina, Beth Rumberger, Thomas Stauffer Larsen, Andreas Rosenwald

Blood (2024) 144 (Supplement 1): 2991.

https://doi.org/10.1182/blood-2024-199176

Published: 2024

Journal Articles

Activity of CAR-T Cells and Bispecific Antibodies in Multiple Myeloma with Extramedullary Involvement

Blood (2024) 144 (Supplement 1): 3792.4.

https://doi.org/10.1182/blood-2024-206735

Published: 2024

Journal Articles

Sequential antigen loss and branching evolution in lymphoma after CD19- and CD20-targeted T-cell–redirecting therapy

Johannes Duell, Alexander M. Leipold, Silke Appenzeller, Viktoria Fuhr, Hilka Rauert-Wunderlich, Matteo Da Via, Oliver Dietrich, Christophe Toussaint, Fabian Imdahl, Florian Eisele, Nazia Afrin, Lars Grundheber, Hermann Einsele, Niels Weinhold, Andreas Rosenwald, Max S. Topp, Antoine-Emmanuel Saliba, Leo Rasche

Blood (2024) 143 (8): 685–696.

https://doi.org/10.1182/blood.2023021672

Published: 2024

Includes: Supplemental data

Journal Articles

Estimates of Survival and Life Expectancy with Tafasitamab Plus Lenalidomide in the L-Mind Study Compared with Real-World Standard-of-Care for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Johannes Duell, Martin Dreyling, Gianluca Gaidano, Nagesh Kalakonda, Eva Maria Gonzalez Barca, Anna Marina Liberati, Zsolt Nagy, Daniel Moik, Mirko Vukcevic, Aasim Amin, Abhishek Bakuli

Blood (2023) 142 (Supplement 1): 6286.

https://doi.org/10.1182/blood-2023-174043

Published: 2023

Journal Articles

Real World Results of Brexucabtagene Autoleucel for Patients with Relapsed/Refractory Mantle Cell Lymphoma - First German/Swiss Analysis

Blood (2023) 142 (Supplement 1): 4394.

https://doi.org/10.1182/blood-2023-182415

Published: 2023

Journal Articles

The Impact of Treatment-Free Intervals on T-Cell Exhaustion and Clonotypic Diversity in Myeloma Patients Treated with BCMA Bispecific Antibodies

Florian Eisele, Nazia Afrin, Emilia Stanojkovska, Mara John, Moutaz Helal, Lars Grundheber, Philipp Weis, Christine Riedhammer, Sofie-Katrin Kadel, Max Steinhardt, Johannes Duell, Johannes M Waldschmidt, Hermann Einsele, Angela Riedel, K. Martin Kortüm, Leo Rasche

Blood (2023) 142 (Supplement 1): 1938.

https://doi.org/10.1182/blood-2023-189042

Published: 2023

Journal Articles

Tafasitamab and Lenalidomide in Relapsed/Refractory B-Cell Lymphoma: A Multicenter Retrospective Real-World-Study of Patients from Germany and Austria

Blood (2023) 142 (Supplement 1): 1771.

https://doi.org/10.1182/blood-2023-185992

Published: 2023

Journal Articles

Prolonged Cytopenia Following CAR T-Cell Therapy in Relapsed/Refractory Multiple Myeloma: A Prospective Comprehensive Biomarker Study

Xiang Zhou, Vivien Wagner, Emilia Stanojkovska, Christine Riedhammer, Xianghui Xiao, Mara John, Lukas Scheller, Umair Munawar, Seungbin Han, Johannes M Waldschmidt, Max S. Topp, Johannes Duell, Hermann Einsele, Angela Riedel, Martin Kortüm, Leo Rasche

Blood (2023) 142 (Supplement 1): 95.

https://doi.org/10.1182/blood-2023-180534

Published: 2023

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

CD19 expression is preserved following CD19-directed monoclonal antibody therapy with tafasitamab

Fixed-duration epcoritamab monotherapy induces high response and MRD-negativity rates in elderly patients with newly diagnosed large B-cell lymphoma (LBCL) and comorbidities: Results from EPCORE DLBCL-3

Phase II frontline chemolight R-pola-glo trial induces high and durable response rates in elderly and medically unfit/frail patients with aggressive B-cell lymphoma

Endothelial dysfunction and proinflammatory state determine severe hematotoxicity and adverse outcome of CAR-T therapy

Increased teclistamab dosing interval improves T-cell diversity and reduces infection risk, while T-cell exhaustion remains minimal irrespective of schedule

Efficacy and safety of vipor (P) in relapsed or refractory large B-cell lymphoma

Spatial transcriptomics reveals profound subclonal heterogeneity and T-cell dysfunction in extramedullary myeloma

Tracking Bone Marrow Regeneration after CAR-T Cell Therapy in Myeloma at Spatial Single-Cell Resolution Reveals Determinants of Prolonged Cytopenia

Classic Anti-Myeloma Treatments Alter Circulating Immune Cell Subsets with Potential Implications for T Cell Immunotherapies in Multiple Myeloma

Epcore DLBCL-3 First Disclosure: Fixed-Duration Epcoritamab Monotherapy in Older (≥75 y), Anthracycline-Ineligible Patients with Previously Untreated Large B-Cell Lymphoma

IDH2 Mutations from Clonal Hematopoiesis and Acquired IKZF1 Deletions Define a Novel B-ALL Subtype after Lenalidomide Therapy for Multiple Myeloma

The Role of Clonally Expanded CD8 + Non-CAR-T Cells in Neurocognitive and Hypokinetic Movement Disorder after BCMA-Targeting CAR-T Cell Therapy

Maintenance of CD19 Expression after Tafasitamab Treatment in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) from Clinical Trial and Real-World Settings

Activity of CAR-T Cells and Bispecific Antibodies in Multiple Myeloma with Extramedullary Involvement

Sequential antigen loss and branching evolution in lymphoma after CD19- and CD20-targeted T-cell–redirecting therapy

Estimates of Survival and Life Expectancy with Tafasitamab Plus Lenalidomide in the L-Mind Study Compared with Real-World Standard-of-Care for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Real World Results of Brexucabtagene Autoleucel for Patients with Relapsed/Refractory Mantle Cell Lymphoma - First German/Swiss Analysis

The Impact of Treatment-Free Intervals on T-Cell Exhaustion and Clonotypic Diversity in Myeloma Patients Treated with BCMA Bispecific Antibodies

Tafasitamab and Lenalidomide in Relapsed/Refractory B-Cell Lymphoma: A Multicenter Retrospective Real-World-Study of Patients from Germany and Austria

Prolonged Cytopenia Following CAR T-Cell Therapy in Relapsed/Refractory Multiple Myeloma: A Prospective Comprehensive Biomarker Study

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only